Nachrichten zur Oncolytics Biotech Inc. Aktie

ONCY: Seeking Registration Pathway for Part B of REO 033 Trial

By David Bautz, PhDNASDAQ: ONCYREAD THE FULL ONCY RESEARCH REPORTBusiness UpdateSeeking Alignment on Turning REO 033 Into a Registration-Directed TrialOn…

ONCY: Aligns with FDA on Pivotal Trial for Pelareorep in Anal Cancer

By David Bautz, PhDNASDAQ: ONCYREAD THE FULL ONCY RESEARCH REPORTBusiness UpdateAligns with FDA on Pivotal Trial in Anal CancerIn April…

CEO Chat with Jared Kelly, CEO of Oncolytics Biotech

NASDAQ: ONCYDavid Bautz: Welcome to the next episode of our CEO Chat series. My name is David Bautz, and Im…

ONCY: Initiating Coverage of Oncolytics Biotech; A Focused Path to Unlocking the Potential of Pelareorep

By David Bautz, PhDNASDAQ: ONCYREAD THE FULL ONCY RESEARCH REPORTWe are initiating coverage of Oncolytics Biotech (NASDAQ: ONCY) with a…

THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality

Issued on behalf of Oncolytics Biotech Inc. Issued on behalf of Oncolytics Biotech Inc.…

Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock?

Oncolytics Biotech (ONCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…

Neue Möglichkeiten der Krebsbehandlung durch hochmoderne Immuntherapien

Vancouver, Bc (ots/PRNewswire) - Veröffentlicht im Auftrag von Oncolytics Biotech Inc.USA News Group Nachrichtenkommentar - Die jüngsten Fortschritte in der…